MannKind Corporation provided an update on the status of its new drug application for Afresa, an ultra rapid-acting insulin that has completed phase-3 clinical trials. As previously announced, the company's internal goal was to submit the NDA to the FDA by the end of February.
The details can be read here.
No comments:
Post a Comment